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Metabolic effects of hemodialysis with and without glucose in the
dialysate. This study was conducted in eight acute renal failure patients
undergoing mechanical ventilation to test if the addition of glucose in
the dialysate prevents metabolic and hormonal changes induced by
hemodialysis. Hemodialysis was performed with a bicarbonate dialy-
sate, a polyacrilonitrile membrane and a continuous heparinization.
Two four-hour hemodialysis sessions were performed in each patient:
one without glucose (GFD) and one with glucose (GD) in the dialysate
at a concentration close to each patient's initial plasma glucose concen-
tration. Oxygen consumption and carbon dioxide elimination, glucose
insulin, aceto-acetate and free fatty acids were measured before, during
and after the sessions. Oxygen consumption and carbon dioxide elim-
ination were measured with a system using a mass spectrometer.
Hemodynamic state and temperature remained constant. Before hemo-
dialysis, respiratory quotient (RQ) values were the same in both groups.
There was no change in RQ during GD. There was a decrease in RQ
during GFD. Glucose and insulin concentrations decreased during GFD
and remained unchanged during GD. Aceto-acetate concentration re-
mained constant under both conditions. Free fatty acids concentration
increased to the same extent during GD and GFD. The authors
conclude that the addition of glucose in the dialysate prevents the
decrease in RQ induced by hemodialysis. This effect is most likely
related to a decreased mobilization of non-glucidic fuels.
Hemodialysis (HD) has been reported to be associated with a
decrease in respiratory quotient (RQ) in mechanically venti-
lated patients with acute renal failure. These modifications were
not affected by changing either the membrane (polyacrilonitrile
vs. cuprophan) or the dialysate buffer (acetate vs. bicarbonate)
[1]. This study was conducted in patients with acute renal
failure in order: (1) to examine substrate and hormone varia-
tions associated with the decrease in RQ; (2) to determine
whether the addition of glucose in the dialysate prevents the
HD induced decrease in RQ.
Methods
Patients
Eight patients (one female, seven males) treated for acute
renal failure and requiring mechanical ventilation were studied.
Clinical data are given in Table 1. All patients were ventilated
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on the control mode (Siemens Servo Ventilator) and had a Pa02
above 8 kPa with a Fi02 under 0.4, No neuromuscular relaxants
were administered to any of the patients. They received con-
tinuous intravenous heparin to prevent thromboembolic com-
plications. The study was performed after the resolution of the
initial phase of acute renal failure to avoid the associated
periods of hemodynamic instability. In particular, during the
study period the patients showed no evidence of septic shock or
hyperkalemia and the central temperature was stable. The
patients had a stable hemodynamic state, presented no evi-
dence of diabetes or hepatic insufficiency, and had no hemor-
rhagic risk. All patients received central venous and peripheral
arterial catheters. Throughout the study, glucose infusion was
maintained constant (2 mg/kg/mm). The administration of lipid
and protein solutions was discontinued six hours before the
beginning of the study.
Protocol
This protocol was approved by the Ethics Committee of our
institution. Each patient was dialyzed twice at a 24 hour interval
with a bicarbonate dialysate (31 mmol/liter). One HD was
achieved with a dialysate free of glucose (GFD) and the other
HD was achieved with a dialysate in which glucose was added
to reach a concentration close to the initial plasma glucose
concentration of the patient (GD). The order of the two sessions
of HD was randomized for each patient. The duration of HD
sessions was four hours. HD was performed without loss of
weight, using a single pass system (Monitral S Hospal) and a
polyacrilonitrile membrane (Biospal 2400 5, parallel flow, 1 m2,
Hospal). Access to blood was provided by a single venous
catheter, Sessions were performed with a double blood pump.
The dialysate flow was 500 ml/min. Mean blood flow was 264
5 mI/mm. Heparin was continuously infused immediately before
the membrane, and the initial dosage was 1000 lU/hr. The
dosage was then adapted to maintain a blood coagulation time
below 18 minutes.
For each HD session, oxygen consumption (VO2), carbon
dioxide elimination (VCO2) and RQ were recorded over 10
consecutive hours: two hours before HD, four hours during HD
and four hours after HD. Arterial blood samples for glucose,
free fatty acid (FFA) and ketone body measurements were
taken each hour. Furthermore, during HD, pre- and posthemo-
dialyzer samples were taken on three occasions for the same
measurements. Blood samples for insulin level were taken
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Table 1. Patient characteristics
Patient
no.
Age
years
Weight
kg
Height
cm Causes of acute renal failure Outcome
1 25 65 178 Post-traumatic
rhabdomyolysis-sepsis
Survived
2 35 61 167 Crush syndrome Survived
3 66 71 169 Abdominal aortic surgery
left renal artery
thrombosis
Survived
4 68 62 166 Esophagogastrectomy-
sepsis-myocardial
infarction
Died
5 27 66 169 Medical rhabdomyolysis Survived
6 85 80 170 Angiocholitis Survived
7 74 63 168 Abdominal aortic surgery-
ischemic colitis
Died
8 27 61 180 Ingestion of caustic
esophageal and gastric
necrosis
Died
before HD, three times during HD, and once after HD. Blood
samples for gas analysis were taken three times (pre-, during,
and post-HD). Plasma urea and creatinine levels were deter-
mined before and after HD. Standard hemodynamic variables
and esophageal or rectal temperature were recorded.
Measurements and calculations
Blood analysis. H concentrations and PCO2 were measured
by a Corning 175, plasma glucose by a glucose analyzer GAIl
Beckman, FFA by an enzymatic colonmetnc method (Wako)
and insulin by a radioimmunoassay (Eis-Oris).
V02 and VCO2 measurements. V02 and VCO2 were mea-
sured by a system using a mass spectrometer (Perkin Elmer
MGA 1100). Details of the procedure and thorough validation
have been given in a previous report [2]. The system can be
briefly described as follows: gas samples were drawn from the
Y piece of the patient's breathing circuit into a mass spectrom-
eter and analyzed for inspired 02 concentration and CO2
waveform recognition. The latter analysis allowed rejection of
artifactual cycles, such as coughing. Then, expired gas was
sampled from the outlet of a mixing chamber for the measure-
ments of the mixed expired 02 and CO2 concentrations. The
duration of the whole analysis sequence was about three
minutes. Expired flow was measured by a pneumotachometer
(Gould Statham Instruments). All the signals were collected by
a computer (Zenith Data System) which was programmed to
reject artifactual respiratory sequences and to compute V02,
VCO2 and RQ. For each patient, values of V02, VCO2 and RQ
were averaged over thirty minute periods.
Calculations. The amounts of glucose and aceto-acetate
extracted by the dialyzer were calculated as the product of the
blood flow through the dialyzer and the difference between
blood glucose or aceto-acetate before and after the dialyzer.
RQ was calculated as the ratio VCO2/V02.
Predicted resting energy expenditure (PREE) was calculated
according to the reevaluated Harris-Benedict equation [3].
Energy expenditure (EE) was calculated using the formula of
Bursztein et al [4].
The results are presented as the mean SE and further
statistical analysis used analysis of variance and Ducan's mul-
tiple range test.
Table 2. Plasma urea and creatinine levels arterial PCO2 (PaCO2) and
H concentrations during hemodialysis (HD) with (GD) and without
(GFD) glucose in the dialysate
Urea
mmol/liter
Creatinine
pjnol/liter
PaCO,
mm Hg
H
nmol/!iter
mmol/liter
GFD
Before HD 37.0 3.9 376 27 25.3 1.0 38.3 2.0
During HD 26.2 0.8 33.2 l.2a
AfterHD 17.5 l.4a 208 l5 25.9 0.9 31.5 0.9
GD
Before HD 36.3 3.4 373 37 25.1 1.2 36.4 2.0
During HD 26.7 1.0 33.6 1.3
After HD 18.4 l.6a 227 23 25.5 1.1 31.6 l.la
a < 0.05 vs. before HD
Results
Plasma urea and creatinine levels before HD were not differ-
ent between GFD and GD. The efficacy of HD was the same
(Table 2). The patients remained hemodynamically stable
throughout the study period. No patient was hypotensive.
Temperature did not change more than 1°C in any patient (Table
3). H concentration decreased during GFD and GD and
PaCO2 remained stable (Table 2).
The pre-HD ratio EE/PREE was 1.14 0.06 and was not
different between GFD (1.14 0.09) and GD (1.14 0.08).
Before HD values of RQ were the same in both groups. A
significant decrease in RQ occurred from the second half of HD
in the GFD group, lasting up to one hour and a half after HD
(Fig. 1). Conversely, there was no significant change in RQ
during GD. Time course evolution of V02 was not significantly
affected by the presence of glucose in the dialysate (Fig. 1).
Arterial plasma glucose and insulin concentrations decreased
significantly during GFD and remained unchanged during GD
(Fig. 2). Arterial aceto-acetate concentration remained within
the normal physiological range throughout the study under both
HD conditions (Fig. 3). Plasma FFA concentration increased
significantly during HD under both conditions (Fig. 3). The
amount of glucose extracted by the dialyzer during GFD was
24.7 2.0 mmol per hour (1.1 .1 mg/kg/mm) and was
undetectable during GD. There was no significant extraction of
ketone bodies by the dialyzer (Table 4).
Discussion
The main findings of this study were that RQ decreased
during GFD and that this decrease was prevented by the
adjunction of glucose in the dialysate. These results are in
agreement with other studies conducted during maintenance
HD. Sherlock, Ledwith and Letteri [5] found a decreased RQ in
the course of a recirculating acetate HD with no glucose in the
dialysate, even when the value of RQ was corrected according
to the CO2 losses through the dialyzer. De Backer et al [61
observed a decreased RQ during a bicarbonate GFD. By
contrast, Hunt et al [71, and Eiser et al [8] found that RQ was
unchanged during a bicarbonate HD with a 2 or 2.5 g/liter
glucose dialysate. However, none of these studies tested the
effect of glucose per se on V02 and VCO2.
In our study, as indicated by the moderately elevated EE/
PREE ratio, the patients were not in an elevated metabolic state
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Table 3. Mean arterial pressure (MAP), heart rate, central venous pressure (CVP) and central temperature during hemodialysis with (GD) and
without (GFD) glucose in the dialysate
Time
MAP
mm Hg
Heart rate
beat/mm
CVP
cm H20
Temperature
°C
GFD GDGFD GD GFD GDminutes GFD GD
90 84 5 94 4 108 8 104 8 8.9 1.1 10.0 1.2 37.5 0.2 37.6 0.2
150 79 6 85 6 104 9 108 6 8.4 1.4 9.3 1,6 37.6 0.2 37.6 0.2
240 81 7 95 7 112 8 111 7 7.9 1.3 8.6 1.4 37.6 0.2 37.7 0.2
330 82 7 93 6 110 8 110 6 7.6 1.4 8.2 1.3 37.5 0.2 37.8 0.2
390 84 7 92 6 107 9 109 6 8.8 1.3 8.1 1.4 37.6 0.2 37.9 0.2
Hemodialysis took place between 120 and 360 minutes.
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Fig. 1. Respiratory quotient (RQ) and oxygen
consumption (V02) during hemodialysis with(• •) and without (D—LJ) glucose in the
dialysate. * P < 0.05 hemodialysis without
glucose vs. hemodialysis with glucose.
[9, 10]. In addition, to avoid the possible influence of the
diseases underlying the acute renal failure, the patients were
studied after the resolution of the initial phase of acute renal
failure. For all the patients, the two sessions of HD were
performed in the same conditions, except for the addition of
glucose in the dialysate. Minute ventilation was maintained
constantly, and we used a bicarbonate dialysate which pre-
vented the dialysate loss of CO2. H concentration decreased
mildly in both groups. In these conditions, the decrease in RQ
associated with HD in the GFD group indicated metabolic
changes, related to the absence of glucose in the dialysate.
Several mechanisms may account for the observed changes
in RQ. At the beginning of GFD, plasma glucose concentration
decreased as a consequence of the extraction of glucose
through the dialyzer. Despite the persistent loss of glucose
through the dialyzer, the stabilization of plasma glucose con-
centration indicated that a new equilibrium was reached. This
stabilization could have been the result of a decreased utiliza-
tion and/or an increased hepatic production.
It has been demonstrated that a decrease in plasma glucose
concentration leads per se to a decrease in glucose utilization
[11]. In our study, V02 and thus the metabolic rate remained
stable. Therefore the decreased glucose utilization might have
been compensated by an increase in lipid oxidation, favored by
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Hemodialysis I Fig. 2. Arterial plasma glucose and insulin
during hemodialysis with (• •) and
without (D—D) glucose in the dialysate. *
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Fig. 3. Arterial plasma acetoacetate and free
fatty acids (FFA) during hemodialysis with( •) and without (D—D) glucose in the
dialysate. * P < 0.05 hemodialysis without
glucose vs. hemodialysis with glucose.
Table 4. Venous plasma glucose and acetoacetate before and after the
dialyzer during hemodialysis (HD) with (GD) and without (GFD)
glucose in the dialysate
Venous
plasma HD
GFD
Before After
GD
Before After
Glucose
mmol/
Beginning
Middle
4.1 0.3
4.0 0.2
2.5 0.1
2.6 0.1
5.6 0.2
5.7 0.2
5.6 0.2
5.6 0.2
liter End 4.4 0.2 2.8 0.1 5.7 0.3 5.6 0.3
Aceto
acetate
Beginning
Middle
48 750 6 30 542 5 51 949 10 39 734 7
molI
liter
End 46±6 36±2 47±7 44±9
the increase in FFA levels, and/or by an increase in protein
oxidation. Both substrate oxidations are favored by the reduc-
tion of insulin and glucose concentration and may account for
the decreased RQ observed in our study. An enhanced lipid
oxidation is not conflicting with the constant ketone body
concentration observed in our patients. Indeed, the continuous
glucose infusion we used could have prevented hepatic keto-
genesis [12]. The increase in ketone body concentration found
by Wathen et al [13] during HD with an acetate dialysate might
be explained by the conversion of acetate into ketone bodies
[141.
An additional explanation for the stabilization of plasma
glucose concentration is an increased glucose hepatic produc-
tion. This could be the consequence of a glycogenolysis or a
neoglucogenesis. As RQ of glycogenolysis is one [15], this
mechanism could not account for the observed changes. The
fact that insulin and glucose concentrations decreased favors
the neoglucogenesis hypothesis.
During GD, the addition of glucose in the dialysate prevented
the decrease in RQ and the related metabolic changes: an
enhanced utilization of non-glucidic fuels. However, two stud-
ies [16, 17] using urea kinetic measurements failed to demon-
strate the sparing effect of glucose on the proteins. In these two
studies, the protein catabolism could have been triggered by the
use of a cuprophan membrane, which has a poor biocompati-
bility [18]. We observed the same increase in FFA concentra-
tions during GD as during GFD; this was probably due to the
use of heparin. Indeed, Davies et al [19] and Teraoka et al [20]
found that the increase in FFA concentration during HD with
heparin was not observed if heparin was replaced by epopros-
tenol, a prostaglandin, or gabexate mexilate, a synthetic pro-
teinase inhibitor.
In conclusion, in acute renal failure patients, the addition of
glucose in the dialysate prevents the HD decrease in RQ which
is most likely related to a decreased mobilization of non-
glucidic fuels. This might have potential advantages in nutri-
tionally depleted patients.
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